Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Last trade$6.14
Day change-$0.03 (-0.49%)
Day range$5.93 – $6.36
Volume546,239
Market cap$939M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for IMTX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for IMTX.
Recent news
Company coverage with links to the original publishers.
Immatics (IMTX) reported a quarterly loss of $0.58 per share, missing the consensus estimate of $0.49 by 18.37%, and posted revenues of $7.97 million, missing estimates by 22.12%. The stock has underperformed significantly, down 38.8% year-to-date compared to the S&P 500's 10.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Immatics reported Q3 2026 financial results with cash position of $536.3 million and announced enrollment progress in the Phase 3 SUPRAME trial for anzu-cel (IMA203) in advanced melanoma, with topline data expected in H1 2027. Updated clinical data presented at ESMO Congress 2026 showed IMA203CD8 achieved 55% cORR in gynecologic cancers and IMA402 bispecific demonstrated 32% cORR in PRAME-high melanoma with 91% 1-year OS rate. The company continues advancing its PRAME-targeted cell therapy and bispecific programs across multiple cancer indications.
Immatics is expected to report flat earnings compared to the year-ago quarter with 68.8% revenue growth. The company has a positive Earnings ESP of +2.04% combined with a Zacks Rank #3, suggesting it will likely beat consensus EPS estimates. However, the company has a mixed earnings surprise history, missing estimates by 23.26% in the last reported quarter.
CG Oncology (CGON) reported a quarterly loss of $0.64 per share, beating consensus estimates of $0.86 loss, representing a 25.58% earnings surprise. Revenue of $1.6 million surpassed estimates by 48.52%, though down slightly year-over-year. The stock has gained 56.1% year-to-date, significantly outperforming the S&P 500's 7.4% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Immatics announced updated clinical trial data for its PRAME-targeting therapies at the 2026 ESMO Annual Meeting. IMA402 bispecific achieved a 32% confirmed objective response rate in PRAME-high melanoma patients with a 12.5-month median duration of response and 91% one-year overall survival rate. IMA203CD8 cell therapy demonstrated a 55% response rate in gynecologic cancers at clinically relevant doses with an 8.4-month median duration of response. Both therapies showed favorable safety profiles, supporting continued development across multiple solid tumor indications.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.